Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

FRANKLIN LAKES, N.J. , Dec. 20, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 41st Annual J.P.

BD to Present at the 41st Annual J.P. Morgan Healthcare Conference

FRANKLIN LAKES, N.J. , Dec. 8, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the release of its second annual Global Inclusion, Diversity and Equity (ID&E) Report for fiscal year 2022.

BD Releases 2022 Global Inclusion, Diversity and Equity Annual Report

FRANKLIN LAKES, N.J. , Dec. 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named among the top 25% of Newsweek's list of America's Most Responsible Companies.

BD Named in top 25% of Newsweek's 2023 List of America's Most Responsible Companies

Dollar General

Kroger

McKesson

Philip Morris

Raytheon Technologies

UnitedHealth Group

Although the market has rallied since the start of November, on rising hopes of a pivot on interest rates by the Federal Reserve (aka a “Fed pivot”), that doesn't necessarily mean it's time to abandon the best bear market stocks and dive back into “risk-on” types of plays. Even as the Fed, in light of data indicating that inflation may be cooling, could soon slow down the pace of subsequent rate hikes, according to one Fed official, it may not be until 2024 that the central bank starts to cut interest rates again.

The 7 Best Bear Market Stocks to Buy Now

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson stock (NYSE: BDX) has seen a 7% fall this year, faring better than the broader S&P500 index, down 17%.

Is There More Room For Growth In Becton Dickinson Stock?

FRANKLIN LAKES, N.J. , Nov. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022 at 8:00 am Eastern Time.

BD to Present at Evercore ISI 5th Annual HealthCONx Conference

Agilent Technologies

AmerisourceBergen

Automatic Data Processing

American Equity Investment Life

Aflac

Assurant

Atmos Energy

CubeSmart

Calavo Growers

DTE Energy

Emerson Electric

Evergy Inc

Griffon

Huntington Ingalls Industries

Hormel Foods

Lancaster Colony

Matthews International

MDU Resources Group

McCormick

Merck

Motorola Solutions

NIKE

Nelnet

RGC Resources

Royal Gold

Roper Technologies

Snap-on

Spire

Waste Connections

York Water

There were a few double-digit boosts in the first half of November. Most notably, ADP came through with a 20% increase and Snap-On Tools with a 14% increase. Emerson extended its dividend growth streak to 66 years with a 1% boost and Lancaster Colony started its 7th decade of dividend growth with a 6% increase.

Merck, Nike Among 14 Companies To Announce Annual Dividend Increases In The Second Half Of November

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.

BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up

Becton, Dickinson and Company (NYSE:BDX ) Q4 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Francesca DeMartino - SVP & Head, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Mike Garrison - President of the Medical Segment Dave Hickey - President of Life Sciences Segment Rick Byrd - President of Interventional Segment Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Matthew Taylor - Jefferies Josh Jennings - Cowen and Company Frederick Wise - Stifel Operator Hello, and welcome to BD's Earnings Call for the Fourth Quarter and Full Year Fiscal 2022. At the request of BD, today's call is being recorded and will be available for replay through November 17, 2022 on BD's Investor Relations website on bd.com or via phone at 866-342-8591 for domestic calls, and area code +1 (203) 518-9713 for international calls.

Becton, Dickinson and Company (BDX) Q4 2022 Earnings Call Transcript

Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.73% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates

Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.

Becton Dickinson stock down 1.3% premarket as Q4 earnings beat tempered by soft fiscal 2023 guidance

Becton Dickinson & Co. BDX, -0.55% said Thursday its board has approved a 4.6% increase in its quarterly dividend to 91 cents a share. The medical tech and diagnostics company said the new dividend is payable Dec. 30 to shareholders of record as of Dec. 9.

Becton Dickinson raises quarterly dividend by 4.6% to 91 cents a share

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral Q4 GAAP and adjusted diluted EPS from continuing operations of $0.92 and $2.75, respectively FY22 revenue from continuing operations of $18.9 billion decreased 1.4% as reported and increased 0.9% on a currency-neutral basis FY22 revenue performance driven by base revenue growth of 6.9% as reported, 9.4% currency-neutral FY22 GAAP and adjusted diluted EPS from continuing operations of $5.38 and $11.35, respectively Company issues FY23 guidance; announces 51st consecutive year of dividend increases, dividend raised 4.6% FRANKLIN LAKES, N.J. , Nov. 10, 2022  /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2022, which ended September 30, 2022.

BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results

FRANKLIN LAKES, N.J. , Nov. 10, 2022 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, an increase of 4.6% from the previous quarter.

BD Board Increases Dividend for 51st Consecutive Year

Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.

3 Dental Supplies Stocks to Watch Amid Industry Headwinds

DuPont de Nemours

NiSource

The following research was contributed to by Christine Short, VP of Research at Wall Street Horizon. Corporate profit growth heads into the final peak week of Q3 earnings season stronger than it began.

These 3 Companies Are Set Up to Report Bad News This Week

Activision Blizzard

Constellation Energy Corp

Disney

Diamondback Energy

GlobalFoundries

Occidental Petroleum

Rivian Automotive

Welltower

We are now at the mid-point of the third quarter earnings season, with about 52% of the S&P 500 companies having reported actual results.

These Are 10 Big Companies Revealing Earnings Next Week

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie

Abbott Labs

These healthcare companies should stay relevant for years as they continue to innovate with new products.

Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever

American Electric Power Company

Dover

Johnson & Johnson

Mastercard

McDonald's

Procter & Gamble

Rockwell Automation

Visa

November is about to be a spectacular month of dividend increases. We have 9 expected dividend increases in November, including several Dividend Kings. In this article, we will discuss the 9 companies in detail, along with summarizing some of October's featured dividend increases.

9 Expected Dividend Increases In November 2022

News for Becton, Dickinson and Co. Stock (BDX)